Warning over menopause drug and ‘rare but serious’ liver injury risk
Dr Karen Magraith says the single case of liver injury appeared to resolve after the patient stopped taking the drug.
The US medicines watchdog has recommended more frequent liver testing for patients taking the new non-hormonal menopause drug fezolinetant after an isolated but serious liver injury case.
Last month, the Food and Drug Administration (FDA) updated prescribing information for fezolinetant (Veoza) after one patient developed liver injury symptoms within 40 days of initiation.
